Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR3 | O15455 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.36 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6947170 | 0.78 | ALDH1A1 (0.49) | MAPTKDM4EALDH1A1LMNAGAA | |
| SCHEMBL1168440 | 0.76 | MAPT (0.50) | MAPTKDM4ECACNA1CALDH1A1LMNA | |
| SCHEMBL6953548 | 0.75 | ABCB1 (0.42) | KDM4EKMT2A | |
| SCHEMBL6958499 | 0.74 | PPARG (0.45) | TLR3MAPTKDM4EALDH1A1GAA | |
| SCHEMBL8536557 | 0.73 | TLR3 (0.49) | TLR3MAPTCACNA1CALDH1A1AKR1B1 | |
| SCHEMBL6948888 | 0.72 | MAPT (0.47) | TLR3MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL9201086 | 0.70 | TLR3 (0.47) | TLR3MAPTALDH1A1AKR1B1LMNA | |
| SCHEMBL617977 | 0.69 | TLR3 (0.45) | TLR3MAPTALDH1A1AKR1B1LMNA | |
| SCHEMBL9533164 | 0.69 | TLR3 (0.48) | TLR3MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL11470271 | 0.69 | TLR3 (0.44) | TLR3MAPTKDM4EALDH1A1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130342-A1 | Glycoprotein llb/llla antagonists | FISHER MATTHEW J (US) | 2003-07-10 | — | — | US | disclosed |
| EP-0804431-B9 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | LILLY CO ELI (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6448269-B1 | SUCH AS 6-(N-(4-(AMINOIMINOMETHYL)BENZOYL)AMINO)-3,4-DIHYDRO-4,4-DIMETHYL-2H-1 -BENZOPYRAN-2-YL)ACETIC ACID; INHIBITING PLATELET AGGREGATION OR FIBRINOGEN BINDING OR PREVENTING THROMBOSIS | ELI LILLY AND COMPANY | 2002-09-10 | — | — | US | disclosed |
| EP-0804431-B1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | LILLY CO ELI (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6020362-A | ANTICOAGULANTS | ELI LILLY AND COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0804431-A4 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | LILLY CO ELI (US) | 1998-04-29 | — | — | EP | disclosed |
| US-5731324-A | Glycoprotein IIb/IIIa antagonists | ELI LILLY AND COMPANY (US) | 1998-03-24 | — | — | US | disclosed |
| EP-0804431-A1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996022288-A1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130342-A1 | Glycoprotein llb/llla antagonists | SELL, SELPLG, LY96 | TLR3 1387/4885MAPT 4377/4885KDM4E 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.